CLRT Clarient, Inc. (MM)

Clarient, Inc. (Nasdaq: CLRT), a premier anatomic pathology and molecular testing services resource for pathologists, oncologists, and the pharmaceutical industry, today announced that Todd S. Barry, M.D., Ph.D., has joined the Company�s medical staff. He will report to Clarient�s Chief Medical Officer, Kenneth J. Bloom, M.D., F.C.A.P. �Dr. Barry is a thought leader in the study of hematopathology and molecular pathology, and we believe his expertise in leukemia and lymphoma will enhance Clarient�s ability to support our customers in our fastest growing service line,� said Dr. Bloom. Ron Andrews, Clarient�s Chief Executive Officer commented, �Central to successful execution of personalized medicine is the convergence of molecular pathology and oncology, and Dr. Barry�s experience will clearly add significant value to Clarient�s efforts to fulfill the promise of this emerging market opportunity.� Most recently Dr. Barry was the Director of Molecular Pathology & Hematopathology for six years at PhenoPath Laboratories, PLLC, a national reference laboratory located in Seattle. Prior to that, he did his Fellowship Training in Hematopathology at the National Cancer Institute. Dr. Barry served his Residency and Fellowship Training in Anatomic Pathology & Lab Medicine at the University of Washington after earning his M.D. and Ph.D. in Immunology at Duke University School of Medicine, Department of Microbiology & Immunology. He received his Bachelor of Science degree in Biology from the University of North Carolina, Chapel Hill. Dr. Barry has published numerous professional studies and is a frequent presenter at pathology conferences. About Clarient Clarient combines innovative diagnostic technologies with world class expertise to assess and characterize cancer. Clarient�s mission is to become the leader in cancer diagnostics by dedicating itself to collaborative relationships with the healthcare community to translate cancer discovery and research into better patient care. The Company�s principal customers include pathologists, oncologists, hospitals and biopharmaceutical companies. The rise of individualized medicine as the new direction in oncology has created the need for a centralized resource providing leading diagnostic technologies such as flow cytometry and molecular testing. Clarient is that resource, having created a state-of-the-art commercial cancer laboratory providing the most advanced oncology testing and diagnostic services available both onsite and over the web. The Company is also developing new, proprietary �companion� diagnostic markers for therapeutics in breast, prostate, lung and colon cancers, and leukemia/lymphoma. Clarient is a Safeguard Scientifics, Inc. partner company. www.clarientinc.com About Safeguard Founded in 1953 and based in Wayne, PA, Safeguard Scientifics, Inc. (NYSE: SFE) provides growth capital for entrepreneurial and innovative technology and life sciences companies. Safeguard targets technology companies in Software as a Service (SaaS) / Internet-based Businesses, Technology-Enabled Services and Vertical Software Solutions, and life sciences companies in Molecular and Point-of-Care Diagnostics, Medical Devices and Specialty Pharmaceuticals with capital requirements between $5 and $50 million. Safeguard participates in expansion financings, corporate spin-outs, management buyouts, recapitalizations, industry consolidations and early-stage financings. www.safeguard.com Forward-Looking Statements The statements herein regarding Clarient, Inc. (the �Company�) contain forward-looking statements that involve risks and uncertainty. Future events and the Company�s actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to: the Company�s ability to market and fund continued development of this new genomics-based diagnostic test for prostate cancer, the Company�s ability to obtain third party payer reimbursement for this test, the efficacy of the test once introduced in the marketplace and the acceptance of this test by physicians and patients, failure to obtain any requisite regulatory clearances or approvals, the Company�s ability to compete with other technologies and with emerging competitors in novel cancer diagnostics and dependence on third parties for collaboration in developing new tests, and risks detailed from time to time in the Company�s SEC reports, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. Recent experience with respect to laboratory services, revenues and results of operations may not be indicative of future results for the reasons set forth above. The company does not assume any obligation to update any forward-looking statements or other information contained in this document.